First-line tebentafusp significantly improved overall survival (OS) when compared with immunotherapy or chemotherapy in patients with metastatic uveal melanoma in a phase 3 trial. Medscape Medical News
Tag: Hematology-Oncology
Companies Are Profiting From Health Data—Patients Should Too
The rise of medical records has created a booming trade in health data — much of it without patients’ knowledge. Medscape Oncology
Companies Are Profiting From Health Data—Patients Should Too
The rise of medical records has created a booming trade in health data — much of it without patients’ knowledge. Medscape Oncology
Are We Healthcare Heroes or Doomsayers?
A physician faces his daughter’s disregard for social distancing amid the COVID-19 pandemic. Medscape Oncology
Text #FlipYourScrip to Easily Donate Unused Drugs
Throwing away leftover medications is an environmental and financial waste. Now clinicians and individuals can pass them onto needy patients. Medscape Medical News
Stopping the Med School ‘Arms Race’
Does an impressive CV really make a better doctor? Medscape Oncology
Public Commenting Has Been Hijacked by Biopharma
In a recent analysis, 1 in 2 ‘public commenters’ giving input on state-level drug coverage decisions was someone with financial ties to the pharmaceutical industry. Medscape Oncology
‘Surgery Is Never Elegant When Women Are in the OR’
Monica Morrow, MD, is one of the leaders in American breast cancer surgery, but her road to the top has had some bumps and bruises. Medscape Medical News
FDA Continues Crack Down on Unapproved Stem Cell Clinics
The FDA is seeking permanent injunctions to stop two US stem cell clinics from marketing potentially dangerous and unapproved stem cell products. Medscape Medical News
Steady Increase in Eyelid Cancer Found in England
Since 2000, the incidence of squamous cell carcinoma of the eyelid in England has increased by around 2% per year, with men affected nearly twice as often as women. Medscape Medical News
FGFR Inhibitor Chemo Linked With Ocular Toxicity
Patients with metastatic cancer undergoing chemotherapy with fibroblast growth factor receptor (FGFR) inhibitors may experience a novel ocular toxicity, a new case series from Spain suggests. Reuters Health Information
Rare Melanomas Prove ‘Hard to Get’ Using Immunotherapy
Dr Jeffrey Weber assesses the benefit of immunotherapies in two rare subtypes of melanoma and finds that rates of survival and duration of response trail well behind those associated with cutaneous melanoma. Medscape Oncology
Therapeutic Options for Retinoblastoma
Over the past decade, localized chemotherapy and targeted drugs have become therapeutic options for retinoblastoma. Cancer Control: Journal of the Moffitt Cancer Center
Researchers Make Progress in Unraveling Uveal Melanoma
Two studies from the University of Miami Miller School of Medicine shed light on physiological and genetic factors associated with uveal melanoma (UM). Reuters Health Information
New Strategies but Modest Benefit in Uveal Melanoma
New therapies being tried in uveual melanoma include combination everolimus, pasireotide long-acting release, and the MEK inhibitor trametinib. Medscape Medical News
Experts Weigh In on 21st Century Cures Act
Experts highlight the pros and cons of the 21st Century Cures Act. Medscape Oncology
Emperor’s Mukherjee on the Three Laws of Medicine
Eric Topol speaks with author Siddhartha Mukherjee about his latest book, The Laws of Medicine, and how uncertainty, imperfections, priors, outliers, and biases affect these laws. Medscape
Chemosurgery Appears No Less Safe Than Enucleation in Advanced Eye Cancer
Ophthalmic artery chemosurgery (OAC) for advanced-stage retinoblastoma appears at least as safe as enucleation, according to New York-based researchers. Reuters Health Information
Mukherjee and Hudis on ‘Emperor’s’ Journey to PBS
Oncologists Cliff Hudis, past president of ASCO, and Sid Mukherjee talk about the PBS documentary adapted from Mukherjee’s Pulitzer Prize-winning book, The Emperor of All Maladies. Medscape Oncology
Ipilimumab in Uveal Melanoma: Long-Lasting Responses in 25%
The first trial of ipilimumab in patients with uveal melanoma has shown some long-lasting responses in a patient population with poor prognosis. Medscape Medical News